Lupin为其经林业发展局批准的长效注射平台启动伙伴关系方案,以促进药物开发和病人护理。 Lupin launches partnership program for its FDA-approved long-acting injectable platform to boost drug development and patient care.

Lupin有限公司启动了一个战略伙伴关系方案,以扩大美国林业发展局为首种产品核准的精密射线诱导长效注射平台。 Lupin Limited has launched a strategic partnership program to expand its PrecisionSphere™ long-acting injectable platform, approved by the U.S. FDA for its first product. 该平台通过确保统一的粒子大小和形状,改善注射和治疗合规性,提供数周至数月的持续药物释放。 The platform delivers consistent drug release over weeks to months by ensuring uniform particle size and shape, improving injectability and treatment adherence. 该倡议旨在帮助合作伙伴扩大药物生命周期,减少失败,并加快开发治疗区先进的注射器。 The initiative aims to help partners extend drug lifecycles, reduce failures, and accelerate development of advanced injectables across therapeutic areas. Lupin强调其监管专长、可扩展的制造和灵活的协作模式是主要优势。 Lupin highlights its regulatory expertise, scalable manufacturing, and flexible collaboration models as key advantages. 该举措支持更广泛地获得创新的药物交付解决方案,并提高患者结果。 The move supports broader access to innovative drug delivery solutions and enhances patient outcomes.